Abstracts tagged "ANCA associated vasculitis"

Abstract Number: 0728 • ACR Convergence 2024
Glomerular Proteomic Signature in ANCA-associated Glomerulonephritis
Ivana Stojkic¹, Arnon Arazi², Huijuan Song³, Pearlly Yan⁴, Estela Puchulu-Campanella⁴, Hubao Wang³, Lynn Fussner³, Brad Rovin³, Samir Parikh⁵ and Salem Almaani⁶, ¹Nationwide, Columbus, OH, ²Feinstein Institutes for Medical Research, Melrose, MA, ³The Ohio State University, Columbus, OH, ⁴The Ohio State University, Columbus, ⁵Ohio State University, Columbus, OH, ⁶The Ohio State University Medical Center, Columbus, OH
Background/Purpose: Crescentic glomerulonephritis (AAGN) is a common manifestation of ANCA-associated vasculitis (AAV) but does not occur in all patients. It is unclear whether the immune…
Abstract Number: 1593 • ACR Convergence 2024
Efficacy of Increasing the Dose of Mepolizumab in Eosinophilic Granulomatosis with Polyangiitis
Federica Pallotti¹, Philippe Bonniaud², Perrine SMETS³, stephanie Habib⁴, Amandine Perier⁵, Alban Deroux⁶, Julie Mankikian⁷, Antoine Neel⁸, Clémentine Rousselin⁹, Raphaele Seror¹⁰, Camille Taille¹¹, Etienne Crickx¹², Candice La Croix¹³, Philippe Blanche¹⁴, Loïc Guillevin¹⁵, Xavier Puéchal¹⁶ and Benjamin Terrier¹⁷, and French Vasculitis Study Group, ¹Internal Medicine, Centre Hospitalier Universitaire de Caen, Caen, France, ²Centre de Référence Constitutif des Maladies Pulmonaires Rares de l'Adulte, Service de Pneumologie et Soins Intensifs Respiratoires, Centre Hospitalo-Universitaire de Dijon-Bourgogne, Dijon, France, ³Clermont Ferrand University Hospital - National reference center for autoimmune disease, Internal Medicine, Clermont-Ferrand, France, ⁴Service de Pneumologie, Hôpital Cochin, APHP Centre et Université Paris Cité, Paris, France, ⁵CH de Niort, Niort, France, ⁶Clinique Universitaire de Médecine Interne, Department of Internal Medicine, Grenoble University Hospital, Grenoble, France, ⁷CHRU Tours, Service de Pneumologie et d'Explorations Fonctionnelles Respiratoires, Tours, France, ⁸Department of Internal Medicine, CHU Nantes, Nantes, France, ⁹Service de médecine interne et néphrologie, centre hospitalier de Valenciennes, Valenciennes, France, ¹⁰Service de Rhumatologie, Hôpital Bicêtre, AP-HP, le Kremlin Bicetre, Ile-de-France, France, ¹¹Bichat Hospital, Paris, France, ¹²Service de Médecine Interne, Centre national de référence des cytopénies auto-immunes de l'adulte, Hôpital Henri Mondor, APHP, Paris, France, ¹³Department of Otolaryngology, Hôpital Cochin, APHP, Paris, France, ¹⁴Department of Internal Medicine, National Referrence Center for Systemic and Autoimmune Diseases, Hôpital Cochin, APHP, Paris, France, ¹⁵National Referral Center For Rare Systemic Autoimmune Diseases, Paris, Ile-de-France, France, ¹⁶National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, ¹⁷Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) patients frequently develop glucocorticoid (GC)-dependent asthma and/or ENT manifestations, leading to long-term GC requirement and side effects. Mepolizumab, an…
Abstract Number: 1611 • ACR Convergence 2024
Impact of Mepolizumab on Patient-reported Outcomes in Eosinophilic Granulomatosis with Polyangiitis by Using the ANCA-associated Vasculitis Patient-reported Outcomes (AAV-PRO) Questionnaire: A European Multicentre Prospective Study
Paolo Delvino¹, Luca Quartuccio², Joanna Robson³, Federico Alberici⁴, Diego Bagnasco⁵, Alvise Berti⁶, Marco Caminati⁷, Marta Camoni⁸, Maria Cid⁹, Edoardo Conticini¹⁰, Giulia Costanzo¹¹, Claire de Moreuil¹², Stefano Del Giacco¹¹, Georgina Espigol-Frigole¹³, Virginia V Ferretti¹⁴, Franco Franceschini¹⁵, Luca Iorio¹⁶, Anna Kernder¹⁷, Catherine Klersy¹⁴, Alberto Lo Gullo¹⁸, Laura Losappio¹⁹, Elena Manna²⁰, Matteo Maule²¹, Carlomaurizio Montecucco²², Negrini Simone²³, Roberto Padoan²⁴, Francesca Regola²⁵, Luisa Ricciardi²⁶, Jan Schroeder¹⁹, Benjamin Terrier²⁷, Paola Toniati²⁸, Elena Treppo², Maria-Letizia Urban²⁹, Augusto Vaglio³⁰, Giacomo Emmi³¹ and Sara Monti³², and European EGPA Study Group, ¹University of Milano-Bicocca, Milan, Milan, Italy, ²Division of Rheumatology, Department of Medicine (DMED), University of Udine, Udine, Italy, Udine, Italy, ³UWE Bristol, Bristol, United Kingdom, ⁴Nephrology Unit, University of Brescia, ASST Spedali Civili, University of Brescia, Brescia, Italy, Brescia, Italy, ⁵Allergy and Respiratory Diseases, Department of Internal Medicine (DIMI), IRCCS Policlinico San Martino, Genoa, Italy, ⁶University of Trento, Rochester, Italy, ⁷Department of Medicine, Asthma, Allergy and Clinical Immunology Section, University of Verona, Verona, Italy, ⁸Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy, ⁹Hospital Clinic Barcelona. University of Barcelona, Barcelona, Spain, ¹⁰University of Siena, Siena, Siena, Italy, ¹¹Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy, ¹²Service de médecine interne, CHU de Brest, Brest, France, ¹³Hospital Clinic de Barcelona, Barcelona, Spain, ¹⁴Biostatistcs & Clinical Trial Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Pavia, Italy, ¹⁵Scleroderma Unit, Rheumatology and Clinical Immunology Unit, ERN ReCONNET, ASST Spedali Civili, Brescia, Italy, Brescia, Italy, ¹⁶Rheumatology Unit, Department of Medicine DIMED, University of Padua, Padova, Italy, Padova, Italy, ¹⁷HHU Dusseldorf, Dusseldorf, Germany, ¹⁸Rheumatology Unit, Papardo Hospital, Messina, Italy, ¹⁹Division of Allergy and Clinical Immunology, ASST GOM Niguarda, Milan, Milan, Italy, ²⁰Division of Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Pavia, Italy, ²¹Asthma Center and Allergy Unit, Verona Integrated University Hospital, Verona, Verona, Italy, ²²IRCCS policlinico S. Matteo foundation, University of Pavia, Pavia, Italy, ²³Department of Internal Medicine (DIMI), University of Genoa, Genoa, Genoa, Italy, ²⁴Department of Medicine DIMED, Division of Rheumatology, University of Padua, Padua, Italy, ²⁵Unit of Rheumatology and Clinical Immunology, ASST Spedali Civili Brescia and University of Brescia, Brescia, Italy, ²⁶Allergy and Immunology Unit, Department of Clinical and Experimental Medicine, G. Martino Teaching Hospital, University of Messina, Messina, Messina, Italy, ²⁷Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France, ²⁸Spedali civili, 25123, Italy, ²⁹Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ³⁰Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Firenze, Florence, Italy, ³¹University of Trieste, Trieste, Italy, ³²IRCCS Istituto Auxologico Italiano, Milan, Italy
Background/Purpose: Mepolizumab (MEPO) proved its efficacy in the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) in the randomized controlled MIRRA trial. The ANCA-associated vasculitis patient-reported…
Abstract Number: 2486 • ACR Convergence 2024
Glucocorticoids May Mitigate the Risk of Avacopan-Induced Liver Dysfunction in ANCA-Associated Vasculitis: Data from a Multicenter Observational Study in Japan
Tomohisa Uchida¹, Shoichi Fukui¹, Naoki Iwamoto¹, Ayaka Umetsu², Momoko Okamoto², Keita Fujikawa², Akinari Mizokami², Takuya Tomokawa³, Kazusato Hara³, Yoshiro Horai³ and Atsushi Kawakami⁴, ¹Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Department of Rheumatology, Japan Community Healthcare Organization (JCHO) Isahaya General Hospital, Isahaya, Japan, ³Department of Rheumatology, Sasebo City General Hospital, Sasebo, Japan, ⁴Nagasaki University, Nagasaki, Japan
Background/Purpose: Avacopan, a C5a receptor inhibitor, has emerged as a novel treatment for ANCA-associated vasculitis (AAV), providing an alternative to glucocorticoids1. Despite its promising potential,…
Abstract Number: 2693 • ACR Convergence 2024
Risk Factors for Relapse in ANCA-Associated Vasculitis Among Patients with Relapse After Induction of Remission with Rituximab
Ellen Romich¹, Joshua Baker², Ian Green², Rennie Rhee², Carol McAlear², Ulrich Specks³, Rona Smith⁴, David Jayne⁴ and Peter Merkel², and the RITAZAREM Investigators, ¹University of Pennsylvania, Media, PA, ²University of Pennsylvania, Philadelphia, PA, ³Mayo Clinic, Rochester, MN, ⁴University of Cambridge, Cambridge, United Kingdom
Background/Purpose: Relapses are common in ANCA-associated vasculitis (AAV), both i) during maintenance treatment after induction of remission, and ii) after immunosuppressive treatment is discontinued. Relapses…
Abstract Number: 0729 • ACR Convergence 2024
Factors Associated with Pauci-immune Glomerulonephritis in Patients Undergoing Renal Biopsy with Positive ANCA Results
Jiyun Lee¹, Yeo-Jin Lee², Mi-Ra Cho³, Young-Eun Kim⁴, Soo Min Ahn⁴, Ji Seon Oh³, Yong-Gil Kim³, Chang-Keun Lee³, Bin Yoo³ and Seokchan Hong³, ¹University of Ulsan College of Medicine, Seoul, Republic of Korea, ²Asan medical center, Seoul, South Korea, ³Asan Medical Center, Seoul, Republic of Korea, ⁴Asan medical center, University of Ulsan College of Medicine, Seoul, Republic of Korea
Background/Purpose: Pauci-immune glomerulonephritis (GN) is a renal manifestation of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). When patients present with positive ANCA results and urinary abnormalities…
Abstract Number: 1595 • ACR Convergence 2024
Tezepelumab for Relapsing or Refractory Eosinophilic Granulomatosis with Polyangiitis: A European Retrospective Study
Margot Poux¹, Matthieu Groh², Alexandra Nanzerkelly³, Marco Caminati⁴, candice Lacroix⁵, stephanie Habib⁶ and Benjamin Terrier⁷, ¹Université de Paris cité, PARIS 04EME, France, ²Foch, Suresnes, France, ³King's college London, London, ⁴Department of Medicine, Asthma, Allergy and Clinical Immunology Section, University of Verona, Verona, Italy, ⁵Université de Paris cité, Paris, ⁶Service de Pneumologie, Hôpital Cochin, APHP Centre et Université Paris Cité, Paris, France, ⁷Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a small vessel vasculitis associated with asthma and blood and tissue eosinophilia. EGPA is often associated with glucocorticoid…
Abstract Number: 1729 • ACR Convergence 2024
Prophylaxis Against Pneumocystis Jerovecii Pneumonia for Patients with Systemic Autoimmune Diseases: Analysis of the Veterans Affairs Database
Karolina Lungova¹, Katherine Sherman², Mahum Mirza¹, Rohan Mehta¹ and Michael Putman³, ¹Medical College of Wisconsin, Milwaukee, WI, ²Research Division, Zablocki Veterans Affairs, Milwaukee, ³The Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Pneumocystis jirovecii Pneumonia (PJP) is an opportunistic infection that may affect immunocompromised patients. PJP prophylaxis has been recommended for some autoimmune diseases but not others.…
Abstract Number: 2487 • ACR Convergence 2024
Comparing Circulating Protein Profiles in Patients with Active Myeloperoxidase (MPO) vs Proteinase-3 (PR3) Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis
Colebrook Johnson¹, David O'Dea¹, Natalie Atallah¹, Gary Reynolds¹, Bohang Jiang¹, Shruthi Srivatsan¹, Zachary Williams¹ and Zachary Wallace², ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Newton, MA
Background/Purpose: ANCA type (e.g., PR3-, MPO-ANCA) may be a better way to subgroup patients with ANCA-associated vasculitis (AAV) than phenotype (e.g., granulomatosis with polyangiitis [GPA]).…
Abstract Number: 2694 • ACR Convergence 2024
Associations Between Immune Checkpoint Molecules and Nasal Microbiome in ANCA-associated Vasculitis
Yoichi Nakayama¹, Mirei Shirakashi², Erika Furukawa³, Chikako Endo⁴, Tsuneo Sasai⁵, Yuya Tabuchi⁴, Ryosuke Hiwa⁵, Hideaki Tsuji⁵, Koji Kitagori⁶, Shuji Akizuki⁷, Ran Nakashima⁵, Kosaku Murakami³, Hajime Yoshifuji⁵ and Akio Morinobu⁸, ¹Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Hirakata-shi, Osaka-fu, Japan, ²Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, ³Division of Clinical Immunology and Cancer Immunotherapy, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan, ⁴Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Kyoto, Japan, ⁵Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁶Occupational Welfare Division, Agency for Health, Safety and Environment, Kyoto University,, Kyoto, Kyoto, Japan, ⁷Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto City, Japan, ⁸Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Kyoto, Japan
Background/Purpose: Among patients with ANCA-associated vasculitis (AAV), several exhibit sinonasal involvement, especially in granulomatosis with polyangiitis (GPA) and eosinophilic granulomatosis with polyangiitis (EGPA). A recent…
Abstract Number: 0730 • ACR Convergence 2024
Assessment of the Quality of Life in a Single-center Cohort of Patients with ANCA-Associated Vasculitis on Targeted Therapy: Characterization of Global, Disease and Organ-specific Parameters Using Patient Reported Outcomes
Michele Moretti¹, Elena Elefante², Francesco Ferro³, Ludovica Pisapia⁴, Federica Di Cianni⁵, Nazzareno Italiano⁶, ROSARIA TALARICO⁵, Chiara Baldini⁷ and Marta Mosca⁷, ¹University of Pisa, Pisa, Pisa, Italy, ²Rheumatology Unit, Department of clinical and experimental medicine, University of Pisa, Pisa, Pisa, Italy, ³Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, ⁴Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ⁵University of Pisa, Pisa, Italy, ⁶University of Pisa, Rovigo, Italy, ⁷University of Pisa, Department of Clinical and Experimental Medicine - Rheumatology Unit, Pisa, Italy
Background/Purpose: ANCA-associated vasculitides (AAVs) are characterized by severe and multisystemic manifestations that greatly affect patients' quality of life (QoL). The purpose of the study was…
Abstract Number: 1596 • ACR Convergence 2024
Efficacy of Eosinophil-Targeting Therapies According to Disease Severity in Patients with Eosinophilic Granulomatosis with Polyangiitis
Bernhard Hellmich¹, Peter Merkel², David Jayne³, Benjamin Terrier⁴, Florence Roufosse⁵, Parameswaran Nair⁶, Nader Khalidi⁶, David J. Jackson⁷, Shunsuke Furuta⁸, Lena Börjesson Sjö⁹, Sofia Necander⁹, Anat Shavit¹⁰, Claire Walton¹¹ and Michael Wechsler¹², ¹Klinik für Innere Medizin, Rheumatologie, Pneumologie, Nephrologie und Diabetologie, Medius Kliniken, Akademisches Lehrkrankenhaus der Universität Tübingen, Kirchheim unter Teck, Germany, ²University of Pennsylvania, Philadelphia, PA, ³University of Cambridge, Cambridge, United Kingdom, ⁴Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France, ⁵Department of Internal Medicine, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium, ⁶McMaster University and St Joseph’s Healthcare, Hamilton, ON, Canada, ⁷Guy’s Severe Asthma Centre, Guy’s and St Thomas’ NHS Trust; School of Immunology and Microbial Sciences, King’s College London, London, United Kingdom, ⁸Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan, ⁹Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ¹⁰BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ¹¹Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ¹²National Jewish Health, Denver, CO
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare inflammatory disorder characterized by asthma, eosinophilia, and small-to-medium size vessel vasculitis, with individual manifestations widely ranging…
Abstract Number: 1844 • ACR Convergence 2024
Manufacturing of IMPT-514, a CD19/CD20 Bispecific CAR T Cell Product Candidate as a Potential Treatment of Patients with Autoimmune Diseases
Ethan BenDavid, Nathanael Joshua Bangayan, Orit Foord, Michael Weist, Melanie Munguia, Jessica Reyes and Jiajia Cui, ImmPACT Bio, West Hills, CA
Background/Purpose: Immunotherapies targeting antigens expressed on B cells are currently being explored as treatments for autoimmune disorders like antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), idiopathic…
Abstract Number: 2488 • ACR Convergence 2024
Patient Characteristics and Treatment Patterns Before and After Initiation of Avacopan in the United States: An Early View Based on a Claims Database Analysis
Sushmitha Inguva¹, Pallavi Rane¹, Darcy Trimpe¹, Sam Oh¹, Jasjit Multani², Hsiu-Ching Chang², Marie Yasuda², Chi-Chang Chen², Duvuru Geetha³, Peter Merkel⁴ and Zachary Wallace⁵, ¹Amgen Inc., Thousand Oaks, CA, ²IQVIA, Wayne, PA, ³Johns Hopkins University, Baltimore, MD, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Massachusetts General Hospital, Newton, MA
Background/Purpose: The United States (US) Food and Drug Administration approved avacopan to treat adults with severe active granulomatosis with polyangiitis or microscopic polyangiitis in October…
Abstract Number: PP02 • ACR Convergence 2024
Living Well with a Rare Rheumatic Disease – Becoming a “Precision” Patient on the Horizon of Precision Medicine
Ida Hakkarinen, self, Greenbelt, MD
Background/Purpose: My journey with a rare, chronic, relapsing rheumatic disease began in November 2010 with a variety of seemingly unrelated symptoms: migrating joint pain, night…

1
2
3
…
19
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].